Effects of abiraterone acetate plus prednisone on bone turnover markers in chemotherapy-naïve mCRPC patients after ADT failure: A prospective analysis of the italian real-world study ABITUDE

Effects of abiraterone acetate plus prednisone on bone turnover markers in chemotherapy-naïve mCRPC patients after ADT failure: A prospective analysis of the italian real-world study ABITUDE

Background: Bone remodeling is disrupted in metastatic disease, which affects > 70% of metastatic castration-resistant prostate cancer (mCRPC) patients. As a result, abnormal levels of specific bone turnover biomarkers (BTMs) are released. In this prospective ancillary analysis of the Italian rea...

Full description

Bibliographic Details
Main Authors: Daniele Santini, Saverio Cinieri, Donatello Gasparro, Roberto Bordonaro, Pamela Francesca Guglielmini, Vincenzo Emanuele Chiuri, Rolando M D'Angelillo, Giovanni Luca Ceresoli, Daniele Fagnani, Mirko Acquati, Manlio Mencoboni, Gaetano Lanzetta, Donata Sartori, Paolo Carlini, Fabiana Panebianco, Patrizia Beccaglia, Giuseppe Procopio
Format: Article
Language:English
Published: Elsevier 2021-02-01
Series:Journal of Bone Oncology
Subjects:
Abiraterone acetate
Bone alkaline phosphatase
Bone targeting therapy
Bone turnover biomarkers
C-terminal telopeptide
mCRPC
Online Access:http://www.sciencedirect.com/science/article/pii/S2212137420300968

Internet

http://www.sciencedirect.com/science/article/pii/S2212137420300968

Similar Items